Proteomics and Dimerix partner to improve the treatment of kidney disease

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a leader in providing predictive diagnostics, is pleased to announce that it has partnered with innovative drug developer Dimerix Limited (ASX:DXB) to improve the treatment of chronic kidney disease (CKD).

Media release

News Archive

2017 2016 2015 2014 2013 2012 2011 2010
  • This field is for validation purposes and should be left unchanged.